Is multiple sclerosis progression associated with the HLA-DR15 haplotype?

Stürner, Klarissa Hanja; Siembab, Inessa; Schön, Gerhard; Stellmann, Jan-Patrick; Heidari, Nika; Fehse, Boris; Heesen, Christoph; Eiermann, Thomas H; Martin, Roland; Binder, Thomas M C

Abstract: Background The prevalence of multiple sclerosis is associated with the major histocompatibility complex class II DR15 haplotype HLA-DRB1*15:01 HLA-DRB5*01:01. Objective To assess whether multiple sclerosis progression is associated with the main susceptibility haplotype HLA-DRB1*15:01 HLA-DRB5*01:01. Methods Patients (n = 1230) and healthy controls (n = 2110) were genotyped for HLA-DRB1 and HLA-DRB5. The baseline Expanded Disability Status Scale (EDSS) score was determined and patients were followed for at least 3 years. Results After follow-up of the consecutive cohort 349 patients were classified as having clinical isolated syndrome and 881 patients as having multiple sclerosis. The susceptibility allele HLA-DRB1*15:01 was more frequent in clinical isolated syndrome (odds ratio 1.56) and multiple sclerosis (odds ratio 3.17) compared to controls. HLA-DRB1*15:01 was the only enriched HLA-DRB1 allele in multiple sclerosis patients. Comparison of clinical characteristics between HLA-DRB1*15:01 HLA-DRB5*01:01 negative and positive patients with multiple sclerosis showed that baseline EDSS score, disease duration and frequency of the category secondary progressive multiple sclerosis with relapse were increased in the HLA-DRB1*15:01 HLA-DRB5*01:01 positive group. Conclusion The study confirmed HLA-DRB1*15:01 and HLA-DRB5*01:01 as the main susceptibility alleles and showed weak indirect evidence for a role in progression of the disease.

DOI: https://doi.org/10.1177/2055217319894615

Zurich Open Repository and Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Is multiple sclerosis progression associated with the HLA-DR15 haplotype?

Klarissa Hanja Stürner, Inessa Siembab, Gerhard Schön, Jan-Patrick Stellmann, Nika Heidari, Boris Fehse, Christoph Heesen, Thomas H Eiermann, Roland Martin and Thomas MC Binder

Abstract

Background: The prevalence of multiple sclerosis is associated with the major histocompatibility complex class II DR15 haplotype HLA-DRB1*15:01–HLA-DRB5*01:01.

Objective: To assess whether multiple sclerosis progression is associated with the main susceptibility haplotype HLA-DRB1*15:01–HLA-DRB5*01:01.

Methods: Patients (n = 1230) and healthy controls (n = 2110) were genotyped for HLA-DRB1 and HLA-DRB5. The baseline Expanded Disability Status Scale (EDSS) score was determined and patients were followed for at least 3 years.

Results: After follow-up of the consecutive cohort 349 patients were classified as having clinical isolated syndrome and 881 patients as having multiple sclerosis. The susceptibility allele HLA-DRB1*15:01 was more frequent in clinical isolated syndrome (odds ratio 1.56) and multiple sclerosis (odds ratio 3.17) compared to controls. HLA-DRB1*15:01 was the only enriched HLA-DRB1 allele in multiple sclerosis patients. Comparison of clinical characteristics between HLA-DRB1*15:01–HLA-DRB5*01:01 negative and positive patients with multiple sclerosis showed that baseline EDSS score, disease duration and frequency of the category secondary progressive multiple sclerosis with relapse were increased in the HLA-DRB1*15:01–HLA-DRB5*01:01 positive group.

Conclusion: The study confirmed HLA-DRB1*15:01 and HLA-DRB5*01:01 as the main susceptibility alleles and showed weak indirect evidence for a role in progression of the disease.

Keywords: Multiple sclerosis, HLA-DRB1*15:01, HLA-DRB5*01:01, EDSS, progression

Date received: 19 June 2019; Revised received: 4 November 2019; accepted: 9 November 2019
Various approaches have been pursued to assess the impact of the HLA-DR15 haplotype on disease progression, as reviewed by van der Walt et al.\textsuperscript{10} In eight of 18 studies, no effect of the HLA-DR15 haplotype was seen, in six of 18 younger ages at diagnosis (onset) were reported, and in four of 18 marginally worse EDSS outcome was observed. The few studies that report an influence showed a protective effect of the HLA-DRB1*04 and the HLA-DRB1*01/HLA-DRB1*15 allele combination for the primary-progressive course,\textsuperscript{11} an earlier conversion of HLA-DR15 carriers to secondary progressive multiple sclerosis (SPMS),\textsuperscript{12} and a worse disease outcome.\textsuperscript{13} HLA-DR15 and HLA-DR4 were associated with relapsing–remitting multiple sclerosis (RRMS) and SPMS, while primary progressive multiple sclerosis (PPMS) was additionally related to HLA-DR4/HLA-DQw8, HLA-DR7/HLA-DQw9 and HLA-DRw8/HLA-DQw4 haplotypes.\textsuperscript{14} Numerous pharmacogenetic studies have explicitly examined the effect of HLA-DR allele status as well as other genes on treatment response of first-line therapies in MS. To date all have concluded that neither HLA-DR15 nor any other HLA allele showed an association with response to either interferon-beta or glatiramer acetate treatment (reviewed in Mahurkar et al.).\textsuperscript{15}

In this study we examined a large cohort of consecutive patients referred to a northern German centre for MS to address whether the HLA-DRB1*15:01~HLA-DRB5*01:01 haplotype is associated with clinical progression.

**Methods**

**Study subjects**

A total of 1230 consecutive individuals was recruited between 1994 and 2010 at the MS outpatient unit and day care clinic of the University Medical Center Hamburg-Eppendorf, typed for HLA, and clinically evaluated at each visit; 2110 ethnically matched platelet and stem cell donors recruited between 1995 and 2010 at the Department of Transfusion Medicine served as controls. The local ethics committee (Ethik-Kommission der Ärztekammer Hamburg) approved the study (no. 2758) and written informed consent was obtained from all subjects.

**HLA genotyping**

DNA was extracted from ethylenediamine tetraacetatic acid blood as described previously.\textsuperscript{16} Samples were typed for HLA class II (DRB1 and DRB5) using the reverse sequence specific oligonucleotide dot blot method. Exon 2 for both genes was amplified and interrogated.\textsuperscript{17–19} Helmberg-Score software was used for allelic assignment in cooperation with the most recent nomenclature report and library.\textsuperscript{20,21} Remaining ambiguities were resolved to two-field allele resolution (DRB1) by sequencing of amplimers obtained after sequence-specific poly-merase chain reaction with appropriate primers (Olerup/CareDx, Stockholm, Sweden).

**Clinical evaluation**

Clinical tests comprised the symbol digit modality test, 9-hole-peg-test, timed 25-footwalk and timed tandem walk, which were performed at each clinical visit. Performance was rated by the EDSS.\textsuperscript{22} In Kaplan–Meier analysis, the time interval to progress from an EDSS score below 4 to an EDSS score below 9 served as the clinical endpoint.

**Statistical analysis**

Allele carrier frequencies were calculated by gene counting.\textsuperscript{23} The control cohort was in Hardy–Weinberg equilibrium (see Supplementary Table 1). Odds ratios (ORs) were calculated to measure MS risk. Significance was evaluated by two-sided \( t \)-test for continuous variables and Fisher’s exact test or Pearson test for categorical variables. Kaplan–Meier curves were tested by log-rank and hazard ratios by likelihood ratio. Values of \( P \leq 0.05 \) were considered statistically significant. \( P \) values were corrected when appropriate.

**Results**

Follow-up of the consecutive cohort of 1230 patients revealed that 349 patients had clinically isolated syndrome (CIS) and 881 patients had MS (Table 1). The phenotypic frequency of the MS susceptibility allele HLA-DRB1*15:01 increased from 26.7% in controls to 38.0% in CIS and 53.8% in MS. A similar increase was seen for HLA-DRB5*01:01 from 26.5% in controls to 53.0% in MS (see Supplementary Table 2). The HLA-DRB1*15 allelic group was the only one to be singled out as enriched in MS over controls (Figure 1). Significantly under-represented HLA-DRB1 allelic groups were HLA-DRB1*07, 08, 11, 13 and 14. After Bonferroni correction only the HLA-DRB1*01 group remained significantly reduced, which reflects the smaller confidence interval of the OR and the higher prevalence of this group in German Caucasians as compared with, for example, the HLA-DRB1*09 group. To address further the status of these ‘alternative alleles’ we stratified the MS risk analysis for
the DRB1*15:01 carrier status (see Supplementary Table 3). This analysis revealed no significant protective effect of any DRB1 allelic group in the non-DRB1*15:01 carriers except for the DRB1*07 allelic group. However, the effect was weak (OR 0.71) and not significant when corrected for multiple comparisons. Interestingly, DRB1*07 was significantly increased in the DRB1*15:01 carriers (OR 2.60) and this remained significant after Bonferroni correction. Thus the highest MS risk was observed in DRB1*15:01, 07 heterozygotes (OR 5.05).

Next we compared the clinical characteristics between HLA-DRB1*15:01 negative and positive patients with MS to look for confounding variables (Table 2). There was no difference in age, sex and frequency of MS categories between the two groups. Significant but small differences were observed for higher baseline EDSS scores and longer disease duration in the HLA-DRB1*15:01~HLA-DRB5*01:01 positive group. To analyse further the trend seen for SPMS we compared the frequency of MS categories and subcategories (Table 3). Here again an increased frequency of relapsing SPMS was observed for the HLA-DRB1*15:01~HLA-DRB5*01:01 positive group.

In 669 patients with MS and complete neurological examination, the distribution of low (0–4.5) and high (5–8.5) baseline EDSS scores correlated with the MS category (Table 4) and the presence of HLA-DRB1*15:01~HLA-DRB5*01:01 (Table 5). MS patients with high-level baseline EDSS scores were more frequently positive for the susceptibility HLA-DRB1*15:01~HLA-DRB5*01:01 haplotype. It is of note that SPMS with relapse stands out with the highest baseline EDSS (Table 4), which in turn will reduce the probability of further increasing in follow-up. To correct for this we decided to use the time for change from the lower EDSS score group to

| Table 1. HLA-DRB1*15:01 allele and phenotypic frequencies in multiple sclerosis, CIS and German controls. |
|---------------------------------------------------------------|
| **N** | Allele frequency | Phenotypic frequency | Odds ratio | **P value** |
|-----------------|-------------------|----------------------|------------|-------------|
| Multiple sclerosis | 881 | 0.308 | 0.538 | 3.17 | <0.0001 |
| CIS | 349 | 0.212 | 0.380 | 1.56 | 0.0003 |
| Control subjects | 2110 | 0.146 | 0.267 | – | – |

CIS: clinically isolated syndrome.

**Figure 1.** Forrest plot of odds ratios (ORs) for multiple sclerosis (MS) risk according to HLA-DRB1 allelic group. HLA-DRB1*15 risk group in red, neutral allelic groups (*03, *04, *09, *10, *12, *16) in yellow, underrepresented and potentially protective allelic groups (*07, *08, *11, *13, *14) in green. OR and 95% confidence intervals (CIs); Bonferroni corrected P (p_cor).
the higher EDSS score group as the clinical endpoint in Kaplan–Meier analysis.

Kaplan–Meier analysis for disease progression from baseline EDSS score less than 4 (0–3.5) to EDSS score less than 9 (4–8.5) confirmed most of these findings (Figure 2). While disease progression occurred in 25% of the cases after 8.9 years in RRMS, this happened in PPMS and SPMS after 3.4 and 2.3 years, respectively (Figure 2(a)). The univariate hazard ratio for progression between SPMS versus RRMS was 3.6 (95% CI 2.4–5.5). Men had a higher risk of progression than women (Figure 2(b)), with a univariate hazard ratio of 1.5 (95% CI 1.1–2.1). The presence of HLA-DRB1*15:01 had

Table 2. Comparison of clinical characteristics between HLA-DRB1*15:01 negative and positive patients with multiple sclerosis.

| Category                                | Negative (N=408) | Positive (N = 473) | P value |
|-----------------------------------------|------------------|--------------------|---------|
| Age (years; mean, SD)                   | 45 ± 11          | 46 ± 10            | 0.06    |
| Sex (female)                            | 66%              | 71%                | 0.17    |
| Baseline EDSS score (mean, SD)          | 2.9 ± 1.8        | 3.2 ± 2.0          | **0.049** |
| Disease duration (years; mean, SD)      | 13 ± 9           | 15 ± 9             | **0.046** |
| Age at onset (years; mean, SD)          | 32 ± 11          | 32 ± 10            | 1.00    |
| Relapsing–remitting MS                  | 68%              | 64%                | 0.18    |
| Primary progressive MS                  | 14%              | 13%                | 0.85    |
| Secondary progressive MS                | 18%              | 23%                | 0.08    |

Two-sided t-test for continuous variable, Fisher’s exact test for categorical variable, uncorrected P.

EDSS: Expanded Disability Status Scale; MS: multiple sclerosis.

Note: Bold value represents *P ≤ 0.05.

Table 3. Multiple sclerosis category and DRB1*15:01 status (N=881).

| Category                                                                 | Negative | Positive | *P value* | *P cor.* |
|--------------------------------------------------------------------------|----------|----------|-----------|----------|
| Relapsing–remitting MS without residue                                  | 189 (46%)| 188 (40%)| 0.06      | 0.36     |
| Relapsing–remitting MS with residue                                      | 89 (22%) | 113 (24%)| 0.47      |          |
| Primary progressive MS without relapse                                   | 38 (9%)  | 47 (10%) | 0.82      |          |
| Primary progressive MS with relapse                                      | 19 (5%)  | 17 (3%)  | 0.50      |          |
| Secondary progressive MS without relapse                                 | 36 (9%)  | 39 (8%)  | 0.81      |          |
| Secondary progressive MS with relapse                                    | 37 (9%)  | 69 (15%) | **0.013** | 0.078    |

Fisher’s exact test, Bonferroni corrected *P (P cor.).

MS: multiple sclerosis.

Note: Bold value represents *P ≤ 0.05.

Table 4. Multiple sclerosis category and baseline EDSS groups (total N=669).

| Category                                                   | N       | Low (0–4.5) | High (5–8.5) | *P value* |
|------------------------------------------------------------|---------|-------------|--------------|-----------|
| Relapsing–remitting MS without residue                      | 294     | 98%         | 2%           | 1.0 × 10^-38 |
| Relapsing–remitting MS with residue                         | 134     | 90%         | 10%          |           |
| Primary progressive MS without relapse                      | 71      | 62%         | 38%          |           |
| Primary progressive MS with relapse                         | 29      | 66%         | 34%          |           |
| Secondary progressive MS without relapse                    | 63      | 64%         | 36%          |           |
| Secondary progressive MS with relapse                       | 78      | 39%         | 61%          |           |

Pearson test.

MS: multiple sclerosis.
Discussion

The analysis of this single-centre northern German MS patient cohort confirmed that HLA-DRB1*15:01 and HLA-DRB5*01:01 are the most prominent MS risk alleles. The finding of an enrichment of HLA-DRB1*15:01 and HLA-DRB5*01:01 in CIS and MS, the higher baseline EDSS scores and longer disease duration in the HLA-DRB1*15:01~HLA-DRB5*01:01 positive group suggests that the HLA-DRB1*15:01~DRB5*01:01 haplotype weakly influences the clinical progression of MS. However, this could not be confirmed in the Kaplan–Meier analysis for progression.

Despite its long and well-known association with MS, the mechanism by which HLA-DR15 confers disease susceptibility is not yet understood. Recent data indicate increased T-cell proliferation in MS patients carrying the HLA-DR15 allele and an increased risk of the presence of oligoclonal bands.

Table 5. Baseline Expanded Disability Status Scale (EDSS) groups and HLA-DRB1*15:01 status.

| EDSS        | N  | DRB1*15:01 negative | DRB1*15:01 positive | P value |
|-------------|----|---------------------|--------------------|---------|
| Low (0–4.5) | 542| 48%                 | 52%                | <0.04   |
| High (5–8.5)| 127| 39%                 | 61%                |         |

Fisher’s exact test.

Figure 2. Kaplan–Meier plots of Expanded Disability Status Scale (EDSS) progression stratified for (a) multiple sclerosis (MS) category, (b) sex, (c) HLA-DRB1*15:01 status in the total cohort (N = 434) and (d) in the subset of patients with relapsing–remitting multiple sclerosis (RRMS). PPMS, primary progressive MS; SPMS, secondary progressive MS.
in the cerebrospinal fluid, nevertheless further studies are needed to shed light on the underlying mechanism and its potential modulation by environmental factors. Environmental agents such as vitamin D, viral infections, diet and noxious agents have been reported to contribute to MS risk in general, and in the case of cigarette smoking and obesity to enhance MS risk synergistically in combination with HLA-DR15. Cigarette smoking has recently also been associated with a worse disease outcome in EDSS parameters. The impact of vitamin D on the clinical course of MS has yet to be examined in clinical studies. Following the hypothesis of a disease-relevant expression of an alternative vitamin D response element (VDRE) in the promoter region of HLA-DR15 allele carriers, it has been suggested that a vitamin D deficiency in early life or in utero allows autoreactive T cells of HLA-DR15 allele carriers to escape central thymic deletion. Nolan and colleagues showed the presence of the constant VDRE in all HLA-DRB1 alleles yet they discussed the potentially protective effect on MS risk in HLA-DRB1*04, *07, *09 (DR53 group) allele carriers attributable to the non-responsive VDRE motif that they had detected in these alleles. In contrast to these studies we did not observe a protective effect of the DR53 group associated alleles in our cohort, as only HLA-DRB1*07 showed a trend for underrepresentation in our MS patient cohort. HLA-DRB1*04 showed an equal distribution in controls and MS patients and only a few cases in our cohort were HLA-DRB1*09 carriers leading to a wide CI. In conclusion, there was no single dominant protective HLA-DRB1 group.

The influence of pairs of classic HLA alleles in strong linkage disequilibrium, HLA-DRB1*15:01–HLA-DQB1*06:02 and HLA-DRB1*01:01–HLA-DQA1*01:01, on age at onset has recently been shown in a large cohort. In addition, evidence for a strong protective effect of the HLA-DQA1*01:01 in the presence of HLA-DRB1*15:01 and an allelic interaction between HLA-DQB1*03:01 with HLA-DQB1*03:02 was found. Re-examining our cohort of MS patients, we found HLA-DQA1*01:01 in combination with HLA-DRB1*15:01 in 39 of 881 patients and HLA-DQB1*03:01 with HLA-DQB1*03:02 in 18 of 881 patients. Further statistical analysis showed no significant correlation with age of onset or clinical outcome parameter in these patient subgroups. With respect to magnetic resonance imaging lesion load and histopathological findings, more extensive CNS inflammation has been described in HLA-DR15 haplotype carriers based on small MS cohorts and recently also in PPMS. However, these data have not been confirmed in larger cohorts.

In the era of disease-modifying therapy (DMT) for MS, it has become even more difficult to assess disease progression (i.e. Kaplan–Meier analysis using an increase in EDSS as a clinical endpoint). This is because, along with possible effects of the DMT, the baseline EDSS is highly associated with the MS category. Therefore analysis must be stratified accordingly, which reduces the power of the present study by reducing the total N from originally 1230 subjects to 434 subjects, who showed EDSS score-progression (Figure 2(a)–(c)) to 272 subjects with RRMS (Figure 2(d)). Under these circumstances, we have no direct evidence for an impact of HLA-DRB1*15:01–HLA-DRB5*01:01 on disease progression. We predict that, if the indirect evidence we see were to become manifest in a larger prospective study controlled for DMT, the effect would be weak, approximately in the range of the effect seen for the gender. In conclusion, apart from MS category and patient sex we could not identify HLA-DRB1*15:01–HLA-DRB5*01:01 as a predictor for clinical progression.

Although this is the largest single-centre MS patient cohort to be evaluated for the HLA-DRB1*15:01–HLA-DRB5*01:01 haplotype as a biomarker to predict clinical progression, the study is limited by its retrospective design and lack of data on HLA class I and non-MHC modifying markers. In particular, the impact of the protective HLA-A*02:01 allele and the risk-increasing HLA-A*03:01 allele, as well as the presence of other recently identified MS-relevant genes are not included. It remains unclear to what extent these genes, alone or in combination, contribute to disease progression. Finally, due to the retrospective design and lack of a mandatory schedule for clinical follow-up, we cannot exclude a bias towards worse disease development as patients with more severe disease activity are more likely to visit the centre more frequently.

Conclusions

For a northern European group, we here confirm the HLA-DRB1*15:01–HLA-DRB5*01:01 haplotype as the single most influential disease susceptibility marker in MS and show evidence for its weak impact on clinical disease progression.
Acknowledgments
The author(s) thank W Fehrle for help with revision of the manuscript.

Conflict of Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: RM was supported by an ERC advanced grant (ERC-2013-ADG 340733).

ORCID iDs
Klarissa Hanja Stüerner https://orcid.org/0000-0003-2199-3315
Christoph Heesen https://orcid.org/0000-0001-8131-9467
Thomas H Eiermann https://orcid.org/0000-0002-5193-0297

Supplemental material
Supplemental material for this article is available online.

References
1. Sospedra M and Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 2005; 23: 683–747.
2. Ramagopalan SV, Dobson R and Meier UC. Multiple sclerosis: risk factors, prodromes, and potential causal pathways. Lancet Neurol 2010; 9: 727–739.
3. Terasaki PI, Park MS, Oelpz G, et al. Multiple sclerosis and high incidence of a B lymphocyte antigen. Science 1976; 193: 1245–1247.
4. Fogdell A, Hillert J, Sachs C, et al. The multiple sclerosis- and narcolepsy-associated HLA class II haplotype includes the DRB5*0101 allele. Tissue Antigens 1995; 46: 333–336.
5. Sawcer S, Ban M, Maranian M, et al. A high-density screen for linkage in multiple sclerosis. Am J Hum Genet 2005; 77: 454–467.
6. International Multiple Sclerosis Genetics Consortium (IMSGC), Beecham AH, Patapoulos NA, Xifara DK, et al. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet 2013; 45: 1353–1360.
7. International Multiple Sclerosis Genetics Consortium. Electronic address: chris.cotapas@yale.edu: International Multiple Sclerosis Genetics C. Low-frequency and rare-coding variation contributes to multiple sclerosis risk. Cell 2018; 175: 1679–1687.e7.
8. Caillier SJ, Briggs F, Cree BA, et al. Uncoupling the roles of HLA-DRB1 and HLA-DRB5 genes in multiple sclerosis. J Immunol 2008; 181: 5473–5480.
9. Hedstrom AK, Sundqvist E, Baarnhielm M, et al. Smoking and two human leukocyte antigen genes interact to increase the risk for multiple sclerosis. Brain 2011; 134: 653–664.
10. Van der Walt A, Stankovich J, Bahlo M, et al. Heterogeneity at the HLA-DRB1 allelic variation locus does not influence multiple sclerosis disease severity, brain atrophy or cognition. Mult Scler 2011; 17: 344–352.
11. Stankovich J, Butzkueven H, Marriott M, et al. HLA-DRB1 associations with disease susceptibility and clinical course in Australians with multiple sclerosis. Tissue Antigens 2009; 74: 17–21.
12. Courmu-Rebeix I, Genin E, Leray E, et al. HLA-DRB1*15 allele influences the later course of relapsing remitting multiple sclerosis. Genes Immun 2008; 9: 570–574.
13. Barcellos LF, Oksenberg JR, Begovich AB, et al. HLA-DQ2 dose effect on susceptibility to multiple sclerosis and influence on disease course. Am J Hum Genet 2003; 72: 710–716.
14. Olerup O, Hillert J, Fredrikson S, et al. Primarily chronic progressive and relapsing/remitting multiple sclerosis: two immunogenetically distinct disease entities. Proc Natl Acad Sci U S A 1989; 86: 7113–7117.
15. Mahurkar S, Suppiah V and O’Doherty C. Pharmacogenomics of interferon beta and glatiramer acetate response: a review of the literature. Autoimmun Rev 2014; 13: 178–186.
16. Lahiri DK and Nurnberger J Jr. A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res 1991; 19: 5444.
17. Erlich H, Bugawan T, Begovich AB, et al. HLA-DR, DQ and DP typing using PCR amplification and immobilized probes. Eur J Immunogenet 1991; 18: 33–55.
18. Allen M, Sandberg-Wollheim M, Sjogren K, et al. Association of susceptibility to multiple sclerosis in Sweden with HLA class II DRB1 and DQB1 alleles. Hum Immunol 1994; 39: 41–48.
19. Tiercy JM, Jeannet M and Mach B. Oligonucleotide typing analysis for the linkage disequilibrium between the polymorphic Drb1 and Drb5 loci in Dr2 haplotypes. Tissue Antigens 1991; 37: 161–164.
20. Helmberg W, Lanzer G, Zahn R, et al. Virtual DNA analysis – a new tool for combination and standardised evaluation of SSO, SSP and sequencing-based typing results. Tissue Antigens 1998; 51: 587–592.
21. Robinson J, Waller MJ, Parham P, et al. IMGT/HLA and IMGT/MHC: sequence databases for the study of the major histocompatibility complex. Nucleic Acids Res 2003; 31: 311–314.
22. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444–1452.
23. Klein J. Chapter 8: The population. In: Natural history of the major histocompatibility complex, 1st edn. New York: John Wiley and Sons, 1986.
24. Mohme M, Hotz C, Stevanovic S, et al. HLA-DR15-derived self-peptides are involved in increased autologous T cell proliferation in multiple sclerosis. *Brain* 2013; 136: 1783–1798.

25. Goris A, Pauwels I, Gustavsen MW, et al. Genetic variants are major determinants of CSF antibody levels in multiple sclerosis. *Brain* 2015; 138: 632–643.

26. Hedstrom AK, Lima Bomfim I, Barcellos L, et al. Interaction between adolescent obesity and HLA risk genes in the etiology of multiple sclerosis. *Neurology* 2014; 82: 865–872.

27. Manouchehrinia A, Tench CR, Maxted J, et al. Tobacco smoking and disability progression in multiple sclerosis: United Kingdom cohort study. *Brain* 2013; 136: 2298–2304.

28. Nolan D, Castley A, Tschochner M, et al. Contributions of vitamin D response elements and HLA promoters to multiple sclerosis risk. *Neurology* 2012; 79: 538–546.

29. Moutsianas L, Jostins L, Beecham AH, et al. Class II HLA interactions modulate genetic risk for multiple sclerosis. *Nat Genet* 2015; 47: 1107–1113.

30. Sombekke MH, Lukas C, Crusius JB, et al. HLA-DRB1*1501 and spinal cord magnetic resonance imaging lesions in multiple sclerosis. *Arch Neurol* 2009; 66: 1531–1536.

31. Tur C, Ramagopalan S, Altmann DR, et al. HLA-DRB1*15 influences the development of brain tissue damage in early PPMS. *Neurology* 2014; 83: 1712–1718.

32. Liguori M, Healy BC, Glanz BI, et al. HLA (A-B-C and -DRB1) alleles and brain MRI changes in multiple sclerosis: a longitudinal study. *Genes Immun* 2011; 12: 183–190.

33. Masterman T, Ligers A, Olsson T, et al. HLA-DR15 is associated with lower age at onset in multiple sclerosis. *Ann Neurol* 2000; 48: 211–219.

34. Fogdell-Hahn A, Ligers A, Gronning M, et al. Multiple sclerosis: a modifying influence of HLA class I genes in an HLA class II associated autoimmune disease. *Tissue Antigens* 2000; 55: 140–148.